Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6200162 | Ophthalmology | 2016 | 8 Pages |
Abstract
Intravitreal E10030 administered at doses up to 3 mg in combination with ranibizumab was well tolerated without evidence of systemic or ocular toxicity in participants with NVAMD. The changes in both mean VA and imaging biomarkers suggest a favorable short-term safety profile for the combination therapy of E10030 and ranibizumab.
Keywords
CNViOpPDGFETDRSEarly Treatment of Diabetic Retinopathy StudyNVAMDChoroidal neovascularizationfluorescein angiographyOctOptical coherence tomographyVisual acuityneovascular age-related macular degenerationVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)platelet-derived growth factorIntraocular pressure
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Glenn J. MD, Dean MD, John A. MD, Jonathan L. MD, Andras MD, Samir MD,